Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

4060 - TransSCOT – translational research based on the Short Course Oncology Therapy (SCOT) cohort


08 Oct 2016


Poster Display


Bodil Elisabeth Engelmann


Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370


B.E. Engelmann1, T. Iveson2, E. Høgdall3, N.H. Holländer4

Author affiliations

  • 1 Department Of Clinical Oncology, Herlev and Gentofte Hospital, 2730 - Herlev/DK
  • 2 Medical Oncology, Southampton General Hospital Southampton University Hospitals NHS Trust, SO16 6YD - Southampton/GB
  • 3 Department Of Pathology, Herlev and Gentofte Hospital, 2730 - Herlev/DK
  • 4 Oncology, Zealand University Hospital, 4700 Næstved - Naestved/DK


Abstract 4060


The Short Course Oncology Therapy (SCOT) study of adjuvant chemotherapy in colorectal cancer aims to ascertain whether 3 months of treatment is as efficacious as 6 months. The study is designed to assess clinical, quality of life and cost-effectiveness outcomes. However, the unique patient material in the SCOT study could help answer questions in the following translational research areas: · Molecular tumour characteristics with prognostic significance in colorectal cancer · Molecular characteristics with predictive significance regarding treatment efficacy and toxicities of 5-FU and oxaliplatin adjuvant treatment in colorectal cancer · Identification of circulating prognostic markers that could be used in personalized follow-up after adjuvant treatment · Identification of genes that could be useful as targets for personalized adjuvant chemotherapy in high-risk patients

Trial design

SCOT recruited patients from 2008 to 2013. 6144 patients were randomised at 243 sites in 6 countries; 311 patients in Denmark. For TransSCOT, all patients that have consented to participation in SCOT are asked for further blood samples and permission to access tumour specimen. TransSCOT is currently recruiting in the UK, Sweden and Denmark. Tumour blocks from 2833 TransSCOT participants are collected in Glasgow, UK, and blood samples from 2964 participants in Oxford, UK, whereas tumour specimens and blood samples from the Danish TransSCOT cohort are collected in the Danish Cancer Biobank (DCB) at Herlev Hospital. Tissue slides and tissue microarrays (TMAs) are prepared for immunohistochemical staining and in-situ hybridization. DNA extraction from blood samples and corresponding tumour tissue is performed for next generation sequencing (NGS). Furthermore, miRNA are extracted in expression arrays. Design of TMAs, panels of markers for NGS and miRNAs of interest are currently defined in the TransSCOT Biorepository Management Group.

Clinical trial identification


Legal entity responsible for the study

Department of Oncology, Næstved Hospital, Næstved, Denmark


Zealand Healthcare Regiońs Foundation for Health Science Research


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings